Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)

NCT ID: NCT05282901 Phase: PHASE2 Sponsor: Institut Curie Status: Completed

SUMMARY

Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to Tebentafusp (better efficacy of anti-PD-1 after Tebentafusp), the combination of pembrolizumab and lenvatinib will be assessed in two independent cohorts: cohort 1 with Tebentafusp-naive patients, and cohort 2 with patients previously treated by Tebentafusp.

The study is a monocentric, phase II trial with a single-arm of treatment in each cohort.

Liver MRI and chest-abdomen-pelvis CT will be performed every 9 weeks until progressive disease (PD), followed by a Follow-up visit within 28 days after last treatment intake. Survival status will be registered after patient discontinuation.

KEY ELIGIBILITY CRITERIA

- 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic uveal melanoma (UM).
- 2. (i) Not having been treated with Tebentafusp for cohort 1 (Tebentafusp-naive patients) OR (ii) Having been previously treated with Tebentafusp for cohort 2.
- 3. Life expectancy \> 3 months.
- 4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG has to be performed at inclusion.
- 5. Male participants must agree to use contraception
- 6. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- 1. Not a woman of childbearing potential (WOCBP) OR
- 2. A WOCBP who agrees to follow the contraceptive guidance
- 7. Measurable disease based on RECIST 1.1. lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- 8. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.

Total sites: 1 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05282901) and public sources. Generated by FindMyCure.ai.